Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 24;19(12):3738.
doi: 10.3390/ijms19123738.

Impact of tRNA Modifications and tRNA-Modifying Enzymes on Proteostasis and Human Disease

Affiliations
Review

Impact of tRNA Modifications and tRNA-Modifying Enzymes on Proteostasis and Human Disease

Marisa Pereira et al. Int J Mol Sci. .

Abstract

Transfer RNAs (tRNAs) are key players of protein synthesis, as they decode the genetic information organized in mRNA codons, translating them into the code of 20 amino acids. To be fully active, tRNAs undergo extensive post-transcriptional modifications, catalyzed by different tRNA-modifying enzymes. Lack of these modifications increases the level of missense errors and affects codon decoding rate, contributing to protein aggregation with deleterious consequences to the cell. Recent works show that tRNA hypomodification and tRNA-modifying-enzyme deregulation occur in several diseases where proteostasis is affected, namely, neurodegenerative and metabolic diseases. In this review, we discuss the recent findings that correlate aberrant tRNA modification with proteostasis imbalances, in particular in neurological and metabolic disorders, and highlight the association between tRNAs, their modifying enzymes, translational decoding, and disease onset.

Keywords: conformational disorders; protein aggregation; proteostasis; tRNA modifications; tRNA-modifying enzymes; transfer RNA; translation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the tRNA secondary structure with respective tRNA-modifying enzymes and modifications (in parenthesis). Connecting lines between RNA residues indicate base pairing. Abbreviations: tRNA, transfer RNA; m1G, 1-methylguanosine; m22G, N2,N2-dimethyl guanosine; Cm, 2′-O-methylcytidine; m3C, 3-methylcytidine Gm, 2′-O-methylguanosine; ncm5Um, 5-carbamoylmethyl-2′-O-methyluridine; m5C, 5-methylcytosine; ncm5mU, 5-methoxycarbonylmethyluridine; mcm5s2U, 5-methoxycarbonylmethyl-2-thiouridine; Q, queuosine; s2U, 2-thiouridine τm5U, 5-taurinomethyluridine; τm5s2U, 5-taurinomethyl-2-thiouridine; I6A, N6-isopentenyladenosine; ms2t6A, 2-methylthio-N6-threonyl carbamoyladenosine; Ψ, pseudouridine; m1A, 1-methyladenosine.
Figure 2
Figure 2
Yeast biosynthesis pathways of modified wobble uridines in different tRNA substrates catalyzed by the Elongator complex (Elp1–Elp6), Trm9, and Urm1 enzymes and the ubiquitin-ligase-like proteins, namely, Uba4, Ncs2, and Ncs6. In yeast, the Elongator complex (Elp1–Elp6) catalyze the wobble uridine (U34) modifications that form 5-carbamoylmethyluridine (ncm5U34) and 5-carboxymethyluridine (cm5U34). Then, the methyltransferase Trm9 uses cm5U34 as a substrate in different tRNAs: tRNA Lys(UUU) tRNA Gln(UUG), tRNA Gly(UCC), tRNA Arg(UCU), and tRNA Glu(UUC). Subsequent addition of a 2-thiol group by an enzyme cascade involving Urm1 and Uba4, Ncs2, and Ncs6 occurs in three of these tRNAs: (tRNALys(UUU), tRNAGln(UUG), and tRNAGlu(UUC)). All modified nucleosides presented in this figure can be found in the MODOMICS database. Red dashed boxes represent the modification catalyzed by the respective enzymes in each step. Abbreviations: tRNA, transfer RNA; ncm5U, 5-carbamoylmethyluridine; cm5U, 5-carboxymethyluridine; mcm5U, 5-methoxycarbonylmethyluridine; mcm5s2U, 5-methoxycarbonylmethyl-2-thiouridine.
Figure 3
Figure 3
Identification of tRNA-modifying enzymes and respective tRNA modification sites involved in neurological and metabolic disorders. Schematic representation of the clover leaf tRNA secondary structure including tRNA-modifying enzymes (in bold), modifications (in parenthesis), and human diseases associated with cytosolic and mitochondrial tRNA defects marked in blue and orange, respectively. Abbreviations: tRNA, transfer RNA; m1G, 1-methylguanosine; m22G, N2,N2-dimethyl guanosine; Cm, 2′-O-methylcytidine; Gm, 2′-O-methylguanosine; ncm5Um, 5-carbamoylmethyl-2′-O-methyluridine; m5C, 5-methylcytosine; ncm5mU, 5-methoxycarbonylmethyluridine; mcm5s2U, 5-methoxycarbonylmethyl-2-thiouridine, τm5U, 5-taurinomethyluridine; τm5s2U, 5-taurinomethyl-2-thiouridine; I6A, N6-isopentenyladenosine; ms2t6A, 2-methylthio-N6-threonyl carbamoyladenosine; Ψ, pseudouridine; m1A, 1-methyladenosine; ALS, amyotrophic lateral sclerosis; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERFF, myoclonus epilepsy associated with ragged red fibers.

Similar articles

Cited by

References

    1. Phizicky E.M., Hopper A.K. tRNA biology charges to the front. Genes Dev. 2010;24:1832–1860. doi: 10.1101/gad.1956510. - DOI - PMC - PubMed
    1. Chan P.P., Lowe T.M. GtRNAdb 2.0: An expanded database of transfer RNA genes identified in complete and draft genomes. Nucleic Acids Res. 2016;44:D184–D189. doi: 10.1093/nar/gkv1309. - DOI - PMC - PubMed
    1. Crick F.H.C. Codon—Anticodon pairing: The wobble hypothesis. J. Mol. Biol. 1966;19:548–555. doi: 10.1016/S0022-2836(66)80022-0. - DOI - PubMed
    1. Phizicky E.M., Alfonzo J.D. Do all modifications benefit all tRNAs? FEBS Lett. 2010;584:265–271. doi: 10.1016/j.febslet.2009.11.049. - DOI - PMC - PubMed
    1. Boccaletto P., MacHnicka M.A., Purta E., Pitkowski P., Baginski B., Wirecki T.K., De Crécy-Lagard V., Ross R., Limbach P.A., Kotter A. MODOMICS: A database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46:D303–D307. doi: 10.1093/nar/gkx1030. - DOI - PMC - PubMed

MeSH terms